Psma-Targeted Low Molecular Weight Urea-Sirna Conjugates For Targeted Knockdown Of Dna-Pk And Radiosensitization Of Prostate Cancer Cell Lines

m h khattab,r r raval,ying zhang,sietze regter,m hedayati,s banerjee,h zhou,dana v ferraris,jesse alt,camilo rojas,barbara s slusher,martin g pomper,theodore l deweese

DOI: https://doi.org/10.1016/j.ijrobp.2014.05.2306

2014-01-01

Abstract:Normal tissue tolerance remains the major limiting factor to dose escalation and its greater therapeutic potential. Previous studies have shown that DNA-activated Protein Kinase catalytic peptide (DNAPK) is critical to non-homologous end joining repair, a pathway triggered in response to DNA double strand breaks. Reductions in DNAPK expression typically result in substantial radiation sensitivity. We have previously reported aptamer-targeted siRNA-mediated reductions in DNAPK resulting in tumor specific radiation sensitization. Here we report siRNAs specific for DNAPK conjugated to a urea-based affinity agent that targets the prostate-specific membrane antigen (PSMA), an enzyme overexpressed on prostate cancer cells. The overall construct involves two levels of targeting, first to prostate cancer by virtue of PSMA expression and second to DNAPK mRNA expression through a specific siRNA (21mer or 27mer). We hypothesize that our agents will selectively recognize PSMA-expressing cells, become internalized and processed, yielding therapeutically-relevant reductions in DNAPK expression. A PSMA-targeted Glu-Lys urea moiety was conjugated to variably modified DNAPK21, 5’NH2-modified DNAPK27 and 3’NH2-modified DNAPK27 siRNA by amide bond formation from the corresponding active ester. Conjugations used at least a 5:1 ratio of Glu-Lys urea to siRNA. Lipofectamine transfection of the conjugates into LNCaP cells was performed to investigate cellular processing of the siRNA. Treatment without lipofectamine was used to determine if conjugates could independently bind PSMA, internalize and reduce DNAPK mRNA. mRNA levels were determined by RT-PCR. Preliminary results of lipofectamine transfected urea-siRNA conjugates reveal up to 90% knockdown of DNAPK mRNA expression relative to control. Direct treatment of the LNCaP cancer cell line with the urea-5’DNAPK27 conjugate resulted in a 53% DNAPK mRNA knockdown (P = 0.068), while the urea-3’DNAPK27 conjugate demonstrated a 37.6% DNAPK mRNA knockdown (P = 0.025). The urea-DNAPK21 conjugate yielded 43% DNAPK mRNA knockdown (P<0.01). Cancer cell specific radiosensitization promises to enable tumor control while reducing radiation-induced side effects. We provide results supporting that PSMA-targeted DNAPK siRNA conjugates can be constructed, delivered and successfully targeted to prostate cancer, resulting in reductions in target mRNA in a fashion that may lead to selective prostate cancer radiosensitization.